세계의 입자선 치료 시장 : 제품 및 서비스별, 시스템별, 유형별, 용도별, 암 유형별, 용도별 - 예측(-2028년)
Particle Therapy Market by Type (Proton Therapy, Heavy Ion), Products (Cyclotron, Synchrotron, Synchrocyclotron), Services, System (Single-room, Multi-room), Cancer Type (Pediatric, Prostate), Application (Treatment, Research) - Global Forecast to 2028
상품코드:1386901
리서치사:MarketsandMarkets
발행일:2023년 11월
페이지 정보:영문 196 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
조사 범위
조사 대상 연도
2020-2028년
기준 연도
2022년
예측 기간
2023-2028년
단위
금액(10억 달러)
부문
제품/서비스별, 시스템별, 유형별, 용도별, 암종별, 지역별
대상 지역
북미, 유럽, 아시아태평양, 라틴아메리카, 중동/아프리카
세계 입자선 치료 시장 규모는 2023년 7억 달러에서 2028년 11억 달러에 달하고, 예측 기간 동안 연평균 8.2%의 CAGR로 성장할 것으로 예상됩니다.
입자선 치료 시장의 급격한 성장이 예상되는 배경에는 암의 증가, 기술의 발전, 암에 대한 개인의 인식 개선, 암 연구에 대한 자금 지원의 증가 등이 있습니다.
입자선 치료 시장은 암종별로는 소아암이 2022년까지 가장 높은 성장률을 보였습니다. 소아암의 증가는 유전적 소인, 영유아의 발달 요인, 미성숙한 면역 체계, 환경 노출, 모성 요인, 세포의 취약성 등의 이유로 인해 발생합니다.
아시아태평양의 인구통계학적 프로파일이 성숙해지면서 치료와 관련된 부작용을 최소화하는 효율적인 암 치료법의 필요성이 강조되고 있습니다. 입자선 치료 시장의 정밀성 중심의 특성과 이러한 공명은 시장 전망을 강화하는 데 있어 매우 중요한 역할을 입증하고 있습니다.
아시아태평양의 병원은 다국어로 환자 치료를 제공하고 입자선 치료 시장과 같은 첨단 치료법에 대한 접근이 용이하기 때문에 이 지역은 특히 다양한 환자들 사이에서 독특한 매력을 발산하고 있습니다. 이러한 언어적 포용성과 첨단 의료 개입의 결합은 이 지역이 선호하는 의료 목적지로서의 선호도를 크게 높여 의료 시장의 경쟁력을 강화하고 입자선 치료 시장의 번영을 촉진하고 있습니다.
이 보고서는 세계 입자선 치료 시장을 조사하여 제품 및 서비스별, 시스템별, 유형별, 용도별, 암종별, 지역별 동향, 시장 진입 기업 개요 등을 정리하여 전해드립니다.
목차
제1장 서론
제2장 조사 방법
제3장 주요 요약
제4장 주요 인사이트
제5장 시장 개요
서론
생태계/시장 맵
가격 분석
공급망 분석
특허 분석
밸류체인 분석
기술 분석
2023-2024년의 주요 회의와 이벤트
규제 상황
상환 분석
무역 분석
Porter's Five Forces 분석
주요 이해관계자와 구입 기준
사례 연구 분석
고객의 비지니스에 영향을 미치는 동향/혼란
제6장 입자선 치료 시장, 제품 및 서비스별
서론
제품
서비스
제7장 입자선 치료 시장, 유형별
서론
양자선 치료
중입자선 치료
제8장 입자선 치료 시장, 시스템별
서론
멀티 룸 시스템
싱글 룸 시스템
제9장 입자선 치료 시장, 용도별
서론
치료
연구
제10장 입자선 치료 시장, 암 유형별
서론
소아암
전립선암
폐암
유방암
두경부암
기타
제11장 입자선 치료 시장, 지역별
서론
북미
유럽
아시아태평양
라틴아메리카
중동 및 아프리카
제12장 경쟁 상황
개요
주요 진출 기업이 채용한 전략
시장 주요 기업의 매출 점유율 분석
시장 점유율 분석
기업 평가 매트릭스
주요 기업의 경쟁 벤치마킹
스타트업/중소기업 평가 매트릭스
경쟁 시나리오와 동향
제13장 기업 개요
주요 진출 기업
IBA WORLDWIDE
VARIAN MEDICAL SYSTEMS, INC.
HITACHI, LTD.
MEVION MEDICAL SYSTEMS
SUMITOMO HEAVY INDUSTRIES LTD.
PROVISION HEALTHCARE, LLC
TOSHIBA MEDICAL SYSTEMS CORPORATION
OPTIVUS PROTON THERAPY, INC.
PROTOM INTERNATIONAL, INC.
ADVANCED ONCOTHERAPY PLC
기타 기업
DANFYSIK A/S
P-CURE, LTD.
PTW FREIBURG GMBH
제14장 부록
ksm
영문 목차
영문목차
Report Description
Scope of the Report
Years Considered for the Study
2020-2028
Base Year
2022
Forecast Period
2023-2028
Units Considered
Value (USD) Billion
Segments
Product, system, type, application, cancer-type and region
Regions covered
North America, Europe, Asia Pacific, Latin America and Middle East & Africa
The global particle therapy market is projected to reach USD 1.1 billion by 2028 from USD 0.7 billion in 2023, growing at a CAGR of 8.2% during the forecast period. The projected surge in market growth for the Particle therapy market is seen due to an increase in cancers, advancements in technologies, and increased awareness among individuals regarding cancer, Increased funding for cancer research.
"The Paediatric application segment to register highest CAGR over the forecast period of 2023-2028."
Based on the cancer type, the Particle therapy market is segmented into pediatric cancer, breast cancer, lung cancer, prostate cancer, head and neck, and other cancers. Pediatric cancer has witnessed the highest growth rate In 2022. The increase in Paediatric cancers can be seen due to the following reasons genetic predisposition, developmental factors in infants, immature immune system, environmental exposures, maternal factors, and cellular vulnerability among others.
"Asia Pacific to register significant growth rate in the market during the forecast period."
For the forecasting period 2023-2028, the APAC region is expected to register a significant growth rate in the market during the forecast period. Asia Pacific comprises India, China, Japan, Australia, South Korea, and RoAPAC. The Asia-Pacific (APAC) region has witnessed a significant increase in the market growth rate for the particle therapy market. There are several drivers that contributed to this growth:
The maturing demographic profile observed in APAC countries accentuates the imperative for efficacious cancer treatment modalities characterized by minimized treatment-related adverse effects. This resonance with the precision-driven attributes of the Particle therapy market substantiates its pivotal role in enhancing the market landscape.
The incorporation of multilingual patient care offerings within APAC hospitals, combined with the accessibility to advanced treatments like the Particle therapy market, confers a unique allure to the region, particularly among a diverse patient spectrum. This fusion of linguistic inclusiveness and state-of-the-art medical interventions significantly enhances the region's desirability as a favored healthcare destination, thereby fortifying its competitive position within the healthcare market landscape and concomitantly propelling the prominence of particle therapy market.
A breakdown of the primary participants referred to for this report is provided below:
By Company Type: Tier 1-40%, Tier 2-30%, and Tier 3- 30%
By Designation: C-level-27%, Director-level-18%, and Others-55%
By Region: North America-50%, Europe-20%, Asia Pacific-15%, Latin America-10%, and the Middle East & Africa-5%
Prominent players in particle therapy market are Varian Medical Systems, Inc.(US), IBA Worldwide(EU) and Hitachi (Japan) among others.
Research Coverage
The report studies the Particle therapy market based on type, system, product, application, cancer type and region.
The report analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth.
The report evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders.
The report studies micro markets with respect to their growth trends, prospects, and contributions to the global Particle therapy market.
The report forecasts the revenue of market segments with respect to five major regions.
Key Benefits of Buying the Report:
The report will help the market leaders/new entrants/smaller firms in this market with investment evaluation viability within the Particle therapy market through a thorough analysis of comprehensive data, thereby facilitating robust risk assessment and enabling well-informed investment determinations. Benefit from meticulous market segmentation encompassing application, end-user, and regional dimensions, affording tailored insights for precise segment targeting. The report also provides an all-encompassing evaluation of encapsulating pivotal trends, growth catalysts, challenges, and prospects, thereby empowering strategic decision-making with astute discernment.
The report provides insights on the following pointers:
Analysis of key drivers (increasing prevalence of cancer patient population, Increasing government initiatives for cancer management, advancements in non-invasive treatments through radiation therapy), restraints (Dearth of skilled radiologist/oncologist, high cost of particle therapy, Complexity of imaging technology for treatments), opportunities (Expansion of key players in emerging countries, Rising healthcare expenditure across developing countries), and challenges (Availability of alternative technology) influencing the growth of the Particle therapy market
Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the particle therapy market.
Market Development: Comprehensive information about lucrative markets - the report analyses the Particle therapy market across varied regions.
Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Particle therapy market
Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players like Varian Medical Systems, Inc.(US), IBA Worldwide(EU) and Hitachi (Japan) among others.
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 INCLUSIONS & EXCLUSIONS
1.4 MARKET SCOPE
1.4.1 MARKETS COVERED
1.4.2 REGIONS COVERED
1.4.3 YEARS CONSIDERED
1.4.4 CURRENCY CONSIDERED
TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
1.6.1 RECESSION IMPACT: PARTICLE THERAPY MARKET
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Key primary sources
2.1.2.2 Key data from primary sources
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS (SUPPLY-SIDE): BY COMPANY TYPE, DESIGNATION, AND REGION
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS (DEMAND-SIDE): BY END USER, DESIGNATION, AND REGION
5.5.1 PATENT PUBLICATION TRENDS FOR PARTICLE THERAPY MARKET
FIGURE 25 TOTAL PATENTS GRANTED FROM 2012-2022
FIGURE 26 TOP PATENT APPLICANTS IN PARTICLE THERAPY
FIGURE 27 TOP PATENT OWNERS IN PARTICLE THERAPY
5.6 VALUE CHAIN ANALYSIS
FIGURE 28 PARTICLE THERAPY MARKET: VALUE CHAIN ANALYSIS
5.7 TECHNOLOGY ANALYSIS
5.8 KEY CONFERENCES & EVENTS IN 2023-2024
5.9 REGULATORY LANDSCAPE
TABLE 2 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 3 EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 4 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PARTICLE THERAPY PRODUCTS BY COUNTRY/REGION
5.10 REIMBURSEMENT ANALYSIS
TABLE 7 MEDICAL REIMBURSEMENT CODES FOR PARTICLE THERAPY PROCEDURES IN US, 2022
5.11 TRADE ANALYSIS
TABLE 8 INSTALLED BASE OF RADIOTHERAPY DEVICES
5.12 PORTER'S FIVE FORCES ANALYSIS
TABLE 9 PARTICLE THERAPY MARKET: PORTER'S FIVE FORCES ANALYSIS
5.12.1 THREAT OF NEW ENTRANTS
5.12.2 THREAT OF SUBSTITUTES
5.12.3 BARGAINING POWER OF SUPPLIERS
5.12.4 BARGAINING POWER OF BUYERS
5.12.5 DEGREE OF COMPETITION
5.13 KEY STAKEHOLDERS & BUYING CRITERIA
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS
TABLE 10 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE APPLICATIONS (%)
5.13.2 BUYING CRITERIA
FIGURE 30 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS
TABLE 11 KEY BUYING CRITERIA FOR TOP THREE APPLICATIONS
5.14 CASE STUDY ANALYSIS
TABLE 12 CASE STUDY: ENHANCING PATIENT SAFETY-RT'S ROLE IN MINIMIZING RADIATION RISK IN AN ELDERLY PATIENT (90-YEAR-OLD FEMALE WITH A MEDICALLY INOPERABLE EARLY-STAGE NSCLC)
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMER'S BUSINESS
FIGURE 31 EMERGING TRENDS AND OPPORTUNITIES AFFECTING FUTURE REVENUE MIX
TABLE 151 PARTICLE THERAPY MARKET: OTHER DEVELOPMENTS (JANUARY 2020-AUGUST 2023)
13 COMPANY PROFILES
13.1 KEY PLAYERS
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)**
13.1.1 IBA WORLDWIDE
TABLE 152 IBA WORLDWIDE: BUSINESS OVERVIEW
FIGURE 39 IBA WORLDWIDE: COMPANY SNAPSHOT (2022)
13.1.2 VARIAN MEDICAL SYSTEMS, INC.
TABLE 153 VARIAN MEDICAL SYSTEMS, INC.: BUSINESS OVERVIEW
FIGURE 40 VARIAN MEDICAL SYSTEMS, INC.: COMPANY SNAPSHOT (2022)
13.1.3 HITACHI, LTD.
TABLE 154 HITACHI, LTD.: BUSINESS OVERVIEW
FIGURE 41 HITACHI, LTD.: COMPANY SNAPSHOT (2021)
13.1.4 MEVION MEDICAL SYSTEMS
TABLE 155 MEVION MEDICAL SYSTEMS: BUSINESS OVERVIEW
13.1.5 SUMITOMO HEAVY INDUSTRIES LTD.
TABLE 156 SUMITOMO HEAVY INDUSTRIES LTD.: BUSINESS OVERVIEW
FIGURE 42 SUMITOMO HEAVY INDUSTRIES LTD.: COMPANY SNAPSHOT (2021)
13.1.6 PROVISION HEALTHCARE, LLC
TABLE 157 PROVISION HEALTHCARE, LLC: BUSINESS OVERVIEW
13.1.7 TOSHIBA MEDICAL SYSTEMS CORPORATION
TABLE 158 TOSHIBA MEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW
FIGURE 43 TOSHIBA MEDICAL SYSTEMS CORPORATION: COMPANY SNAPSHOT (2022)
13.1.8 OPTIVUS PROTON THERAPY, INC.
TABLE 159 OPTIVUS PROTON THERAPY, INC.: BUSINESS OVERVIEW
13.1.9 PROTOM INTERNATIONAL, INC.
TABLE 160 PROTOM INTERNATIONAL, INC.: BUSINESS OVERVIEW
13.1.10 ADVANCED ONCOTHERAPY PLC
TABLE 161 ADVANCED ONCOTHERAPY PLC: BUSINESS OVERVIEW
13.2 OTHER PLAYERS
13.2.1 DANFYSIK A/S
TABLE 162 DANFYSIK A/S: BUSINESS OVERVIEW
13.2.2 P-CURE, LTD.
TABLE 163 P-CURE, LTD.: BUSINESS OVERVIEW
13.2.3 PTW FREIBURG GMBH
TABLE 164 PTW FREIBURG GMBH: BUSINESS OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
